• LEOPARD trial initiation follows recent positive data from OCS-01 eye drops from the Stage 1 Phase 3 DIAMOND trial in patients with Diabetic Macular Edema (DME)
  
• Cystoid Macular Edema (CME) can result from uveitis or from post-surgical complications
• CME is one of the most significant causes of vision loss after ocular surgery¹ and approximately 28% of patients who undergo ocular surgery, including patients with diabetes, uveitis and other risk factors, have a higher risk of CME². In addition, CME can also occur in about 40% of patients with posterior or pan-uveitis³

ZUG, Switzerland, and BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that the first patient has been enrolled in the investigator-initiated LEOPARD trial evaluating the potential of OCS-01 eye drops, Oculis’ novel high concentration preservative-free topical OPTIREACH formulation of dexamethasone, for the treatment of cystoid macular edema (CME).

CME may occur as a complication of ocular conditions, including uveitis and ocular surgery, and is a leading cause of vision loss worldwide. It is one of the most significant causes of postoperative vision loss after cataract surgery¹. Approximately 28% of patients who undergo ocular surgery, including patients with diabetes, uveitis and other risk factors, have a higher risk of developing CME following the procedure². Up to 56% of high-risk patients may experience clinically significant CME following ocular surgery¹.

The LEOPARD trial, administratively sponsored by the Global Ophthalmic Research Center (Los Altos, California) and led by Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine, aims to evaluate the efficacy and safety profile of OCS-01 eye drops in the management of two different forms of CME: Uveitic Macular Edema (UME) and Post-Surgical Macular Edema (PSME). It is a prospective, multi-center, open label, single-armed trial which plans on enrolling 24 eligible subjects (12 with UME and 12 with PSME). Two different doses will be used, and the total treatment period is 24 weeks. The primary endpoints, which will be assessed at 12 weeks, are improvement in central subfield thickness (CST) and visual acuity.

CME is being explored with OCS-01 eye drops, in addition to diabetic macular edema (DME) and inflammation and pain post ocular surgery, both indications currently in Phase 3 clinical development. OCS-01 has demonstrated its potential to reduce macular edema as measured by improvements in retinal thickness in a pilot study with uveitic macular edema patients as well as in the recently completed Stage 1 of the Phase 3 DIAMOND trial in patients with DME.

Professor Nguyen, who is a member of the Oculis Scientific Advisory Board, commented: “I am very excited to investigate the potential of OCS-01 eye drops for the treatment of cystoid macular edema, one of the most common causes of decreased vision in patients following cataract and other ophthalmic surgeries, and in uveitis patients. Given the recently announced DIAMOND Phase 3 Stage 1 data readout in DME, which showed statistically significant reduction in retinal thickness with OCS-01, we believe in its potential to provide a paradigm shift in the treatment of post-surgical and uveitic macular edema, in addition to DME.”

Riad Sherif, M.D., Chief Executive Officer of Oculis, concluded: “Oculis is proud to support this investigator-initiated trial led by Professor Nguyen in cystoid macular edema with OCS-01 eye drops, to explore its potential in this vision-threatening eye condition. OCS-01 is Oculis’ lead compound currently being investigated in two Phase 3 clinical trials in DME as well as inflammation and pain following with ocular surgery with promising efficacy and safety data.”

¹ Laura H.P. Wielders et al. Prevention of CME After Cataract Surgery, CRST Today Europe, 2013 https://crstodayeurope.com/articles/2013-julaug/prevention-of-cme-after-cataract-surgery
² Hennings et al. Prognostic determinants of postoperative pseudophakic macular oedema in a tertiary hospital setting ARVO Annual Meeting Abstract, June 2021, volume 62, Issue 8, https://iovs.arvojournals.org/article.aspx?articleid=2775475
³ Oren Tomkins-Netzer et al. Seven-year outcomes of uveitic macular edema: the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study results, Ophthalmology, May 2021 128 (5): 719-728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943640/

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop retinal candidate for diabetic macular edema (DME); OCS-02, a topical eye drop biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contacts

Mrs. Sylvia Cheung, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor & Media Relations

LifeSci Advisors
Corey Davis, Ph.D.
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-212-915-2577

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding expected future milestones and catalysts; the initiation, timing, progress and results of Oculis’ clinical and preclinical studies; Oculis’ research and development programs, regulatory and business strategy, future development plans, and management; Oculis’ ability to advance product candidates into, and successfully complete, clinical trials; and the timing or likelihood of regulatory filings and approvals, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.